Meta tags:
description= OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.;
keywords= Clinical Oncology News,cancer news,Cancer Expert Insights;
Headings (most frequently used words):
latest, news, all, oncology, conference, coverage,
Text of the page (most frequently used words):
#cancer (56), #oncology (43), the (41), and (36), 2024 (32), #march (30), for (19), #nsclc (19), #with (18), #testing (16), #plus (14), #care (14), cme (13), #biomarker (12), #news (12), hematologic (12), gastrointestinal (11), 28th (10), patients (10), treatment (10), cancers (10), institute (10), view (9), 27th (9), advanced (9), 26th (9), more (9), what (9), therapy (9), first (8), line (8), ryan (8), approval (8), immuno (8), breast (8), cell (7), latest (7), bladder (6), new (6), clinical (6), risk (6), all (6), genitourinary (6), shows (6), courtney (6), flaherty (6), pembrolizumab (6), early (6), lung (6), events (5), osimertinib (5), medicine (5), has (5), study (5), positive (5), research (5), how (5), com (5), conference (5), precision (5), scott (4), cne (4), egfr (4), gynecologic (4), management (4), publications (4), jersey (4), g12c (4), leukemia (4), unresectable (4), carboplatin (4), kras (4), stage (4), expert (4), medical (4), wahner (4), ngs (4), from (4), trials (4), are (4), phase (4), etoposide (4), report (4), ashling (4), improves (4), onclive (4), pfs (4), chris (4), health (4), fda (4), brain (4), mds (3), effective (3), lower (3), approved (3), acute (3), contact (3), japan (3), specialists (3), utah (3), nmpa (3), china (3), car (3), based (3), crossfire (3), practice (3), experts (3), you (3), florida (3), rutgers (3), supportive (3), results (3), hcc (3), therapies (3), needs (3), unmet (3), mutant (3), mutated (3), progression (3), comprehensive (3), consortium (3), impact (3), discusses (3), solid (3), alone (3), survival (3), lymphocytic (3), anlotinib (3), expands (3), sclc (3), coverage (3), 1084 (3), tumors (3), kyle (3), doherty (3), improved (3), settings (2), index (2), into (2), resectable (2), observational (2), among (2), drug (2), tissue (2), disparities (2), world (2), prostate (2), selection (2), across (2), why (2), high (2), decision (2), adjuvant (2), dieugenio (2), earlier (2), benefits (2), neoadjuvant (2), options (2), safety (2), priority (2), jax (2), webcast (2), disease (2), endocrine (2), revumenib (2), kmt2a (2), activity (2), review (2), discuss (2), provide (2), intracranial (2), metastases (2), when (2), not (2), gene (2), mutations (2), explain (2), live (2), access (2), ttfields (2), retrospective (2), efstathiou (2), status (2), after (2), preservation (2), blast (2), muscle (2), invasive (2), effects (2), time (2), alterations (2), approaches (2), choose (2), illustrations (2), commentaries (2), future (2), potential (2), renal (2), resources (2), biosimilars (2), specialty (2), wins (2), capivasertib (2), fulvestrant (2), pik3ca (2), akt1 (2), pten (2), malignancies (2), her2 (2), treated (2), previously (2), covid (2), could (2), side (2), cldn18 (2), insights (2), topline (2), melanoma (2), lymphoma (2), zolbetuximab (2), small (2), sarcomas (2), findings (2), gastric (2), chronic (2), cel (2), novel (2), spotlight (2), liso (2), refractory (2), business (2), snda (2), skin (2), investigation (2), relapsed (2), exon (2), pediatric (2), nursing (2), met (2), metastatic (2), sls009 (2), wagner (2), aml (2), accepts (2), locally (2), been (2), burst (2), savolitinib (2), huntsman (2), significance (2), tgct (2), regarding (2), million (2), neck (2), community (2), luspatercept (2), chemotherapy (2), 25th (2), center (2), partners (2), outcomes (2), updates (2), experience (2), myelodysplastic (2), head (2), post (2), media (2), rwjbarnabas (2), subscribe (2), videos (2), national (2), about (2), global (2), conferences (2), benefit (2), toward (2), key (2), connections (2), legislature (2), pipeline, focus, basket, tumor, science, activities, summit, agnostic, reshaping, registration, syndromes, scientific, tsc1, ipc, peer, your, atrophy, lymphoid, eye, exchange, vignette, talk, can, geographic, prepare, perspectives, rapid, readouts, series, podcasts, pre, workshop, era, interchanges, immune, per, gaps, overcome, mechanistic, giants, vignettes, oncchats, listing, archived, beyond, integrating, affinity, network, psma, evaluating, specialized, state, repeat, diagnostic, schneider, actionable, multiple, harboring, treating, rodriguez, use, olazagasti, kim, allocates, times, profiling, genomic, pellini, elements, interpreting, utilized, performed, concerns, addressing, cohort, turnaround, frontline, multi, enfortumab, advertisement, orr, adagrasib, seymour, caroline, qol, transform, imetelstat, urothelial, vedotin, sbla, ibrutinib, pecoma, malignant, sirolimus, nab, phd, andrew, mantle, low, safe, rituximab, without, institutional, resistance, webinars, learning, should, tkis, context, person, virtual, just, hcps, sponsored, fusion, presentations, mutation, referred, rearrangement, modules, interactive, tools, chromosomal, supplements, featured, around, challenges, immunotherapy, fellows, thoracic, mechanisms, patterns, plasma, ctdna, ihc, analysis, setting, lazertinib, amivantamab, biomarkers, predictive, real, surgeons, pragmatic, mylung, both, rates, contemporary, rna, dna, platform, certain, choosing, centers, vineyard, jason, building, venetoclax, welfare, labour, ministry, japanese, enrollment, completes, trial, regal, data, generates, myeloid, azacitidine, mhlw, announced, have, esas, alternative, provides, syndrome, iyer, sunil, pressures, parenting, handling, recurrent, approves, parental, agarwal, gholam, pierre, oligometastatic, mhspc, bolster, shifting, agents, investigating, ongoing, spectrum, fasco, neeraj, along, consistent, demonstrates, chemo, superior, confers, designated, only, position, its, retains, redesignated, was, leave, oncologists, considerations, 08512, cgtlive, curetoday, oncnursingnews, targetedonc, privacy, conditions, terms, information, sell, info, editorial, cranbury, drive, commerce, 7777, 716, 609, reserved, rights, sciences, life, mjh, home, cancernetwork, board, career, placebo, issues, details, recent, sll, cll, continued, unpacking, chb, kenderian, saad, placebos, see, advertise, iii, advantage, significant, confer, does, crt, durvalumab, concurrent, atezolizumab, subcutaneous, prefer, imscin002, primary, navigating, academic, questions, affected, assay, test, incorporating, uncertainties, standards, current, optimal, emerging, pivotal, covering, lingering, offer, developments, delineate, rosa, kristi, monotherapy, administered, profile, toxicity, acceptable, had, mpn, reverted, clinicians, megan, reduction, during, received, university, skipping, naive, accepted, paradigm, evolving, window, asco, symposium, presented, hollasch, carcinoma, hepatocellular, updated, recurrence, europe, perioperative, followed, commission, european, extend, physicians, impacts, consolidation, granted, approvals, models, language, large, speculation, process, oncologic, improve, added, definitions, clearer, their, intelligence, due, definition, understood, widely, firming, importance, emphasize, investigators, grants, rearranged, seeking, nda, artificial, commonplace, hsct, point, transplantation, hematopoietic, accelerated, neoplasms, myeloproliferative, county, volusia, city, orange, facility, opened, end, causing, meets, non, negative, altered, pretreated, decisions, make, osterman, travis, concern, excitement, oncclub,
Text of the page (random words):
onclive clinical oncology news cancer expert insights news oncclub all oncology news pipeline report media insights medical world news oncchats onclive news network onclive tv peer exchange podcasts rapid readouts the talk conferences conference coverage conference listing events giants of cancer care per events scientific interchanges state of the science summit ipc webinars partners publications oncology live oncology fellows supplements and featured publications all publications cme ce resources interactive tools learning modules presentations sponsored biomarker consortium subscribe choose specialty biosimilars brain cancer breast cancer breast cancer car t cell therapy covid 19 disparities in cancer care gastrointestinal cancer gastrointestinal cancer gastrointestinal cancer gastrointestinal cancer gastrointestinal cancer genitourinary cancers genitourinary cancers genitourinary cancers global oncology gynecologic oncology gynecologic oncology head neck cancers hematologic oncology hematologic oncology hematologic oncology hematologic oncology hematologic oncology hematologic oncology immuno oncology immuno oncology immuno oncology immuno oncology lung cancer melanoma skin cancer oncology business management oncology nursing news pediatric oncology precision medicine in oncology precision medicine in oncology sarcomas tgct supportive care spotlight in person and virtual events just for hcps choose specialty biosimilars brain cancer breast cancer breast cancer car t cell therapy covid 19 disparities in cancer care gastrointestinal cancer gastrointestinal cancer gastrointestinal cancer gastrointestinal cancer gastrointestinal cancer genitourinary cancers genitourinary cancers genitourinary cancers global oncology gynecologic oncology gynecologic oncology head neck cancers hematologic oncology hematologic oncology hematologic oncology hematologic oncology hematologic oncology hematologic oncology immuno oncology immuno oncology immuno oncology immuno oncology lung cancer melanoma skin cancer oncology business management oncology nursing news pediatric oncology precision medicine in oncology precision medicine in oncology sarcomas tgct supportive care spotlight news media conferences events partners publications cme ce resources biomarker consortium subscribe advertisement latest news adagrasib improves pfs orr in previously treated kras g12c mutant nsclc by caroline seymour march 28th 2024 imetelstat shows potential to transform qol in lower risk mds by courtney flaherty march 28th 2024 china s nmpa accepts sbla for enfortumab vedotin plus pembrolizumab in advanced urothelial cancer by chris ryan march 28th 2024 wagner on the investigation of nab sirolimus in advanced malignant pecoma by andrew j wagner md phd march 28th 2024 observational study shows frontline ibrutinib with without rituximab is safe and effective in low risk mantle cell lymphoma by ashling wahner march 28th 2024 latest videos biomarker consortium videos dr schneider on diagnostic testing turnaround times in lung cancer dr rodriguez on treating patients with lung cancer harboring multiple actionable mutations dr olazagasti on the use of biomarker testing in lung cancer dr kim on nsclc treatment selection based on biomarker testing results dr pellini on comprehensive genomic profiling and repeat biomarker testing in nsclc key elements of an ngs testing report interpreting the results of an ngs testing report how is biomarker testing performed and utilized addressing concerns regarding biomarker testing tissue and plasma based mechanisms of resistance to first line osimertinib in egfr mutant nsclc a multi institutional cohort predictive biomarkers for treatment with amivantamab plus lazertinib among egfr mutated nsclc in the post osimertinib setting analysis of tissue ihc and ctdna ngs real world testing and treatment patterns among patients with stage iv nsclc a retrospective observational study contemporary biomarker testing rates in both early and advanced nsclc results from the mylung pragmatic study what is ngs testing what is dna and rna testing in biomarker testing why are you choosing a certain testing platform in biomarker testing how do you explain adjuvant therapy in nsclc when should patients with nsclc be referred to thoracic surgeons in specialized centers of care what are the benefits and side effects of tkis what is a biomarker in the context of tumors what is a gene mutation and a gene fusion what is a chromosomal rearrangement how do you explain neoadjuvant therapy in nsclc what are challenges around access to testing what are the benefits and side effects of immunotherapy latest cme events activities live webcast registration cme what s in your basket tumor agnostic trials and the reshaping of precision medicine in oncology a focus on tsc1 2 mutations view more expert illustrations commentaries cme cne expert illustrations and commentaries evaluating the potential for novel mechanistic approaches to overcome clinical gaps in the care of patients with lr mds view more archived webcast cme medical crossfire why is psma so effective to affinity and beyond view more medical crossfire cme medical crossfire expert perspectives in geographic atrophy how can we prepare for a new era of treatment view more community practice connections cme community practice connections pre conference workshop on immune cell based therapy view more clinical vignette series cme cne clinical vignettes integrating novel car t cell therapies across lymphoid malignancies with an eye toward the future of care view more burst cme cme cne the latest on acute lymphocytic leukemia view more burst cme cme cne updates in myelodysplastic syndromes view more all oncology news utah legislature allocates 75 million to vineyard cancer research center by huntsman cancer institute march 28th 2024 huntsman cancer institute at the university of utah received 75 million from the utah legislature toward a cancer research and academic building china s nmpa accepts snda for savolitinib in locally advanced metastatic met exon 14 nsclc by ashling wahner march 28th 2024 china s nmpa has accepted an snda for approval of savolitinib for treatment naive locally advanced metastatic nsclc with met exon 14 skipping alterations asco gi updates provide window into evolving hcc treatment paradigm by kyle doherty march 28th 2024 experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 gastrointestinal cancers symposium perioperative pembrolizumab wins approval in europe for resectable nsclc at high risk of recurrence by chris ryan march 28th 2024 the european commission has approved neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high risk resectable nsclc the breast cancer index impacts physicians decision to extend endocrine therapy for hr early stage disease by megan hollasch march 28th 2024 incorporating the breast cancer index test assay into practice affected clinicians decision to offer endocrine therapy in hr early stage disease experts discuss current standards selection and uncertainties in bladder and renal cancer care by courtney flaherty march 27th 2024 experts delineate the latest developments and lingering questions in bladder and renal cancers covering pivotal trials emerging therapies and optimal management approaches mk 1084 alone and plus pembrolizumab shows early safety activity in kras g12c solid tumors by kristi rosa march 27th 2024 mk 1084 had an acceptable toxicity profile when administered as a monotherapy in patients with kras g12c mutated previously treated solid malignancies retrospective study shows hsct consolidation after blast reduction improves os in chronic phase reverted mpn by ashling wahner march 27th 2024 patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation efstathiou on the status of bladder preservation therapy for muscle invasive bladder cancer by jax dieugenio march 27th 2024 jason efstathiou md discusses the status of bladder preservation therapy for muscle invasive bladder cancer florida cancer specialists research institute expands access to cancer care in volusia county by florida cancer specialists research institute march 27th 2024 florida cancer specialists research institute has opened a new facility in orange city fl to provide comprehensive cancer care ttfields meets time to intracranial progression end point in nsclc brain metastases by ryan scott march 27th 2024 ttfields plus supportive care improved time to intracranial progression in patients with brain metastases from non small cell lung cancer capivasertib fulvestrant wins approval in japan for advanced hr her2 breast cancer with pik3ca akt1 or pten alterations by courtney flaherty chris ryan march 27th 2024 capivasertib plus fulvestrant has been approved in japan for pretreated pik3ca akt1 or pten altered hr positive her2 negative breast cancer how to make clinical decisions with ai in oncology by travis j osterman do march 27th 2024 speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace causing excitement and concern clearer definitions of added benefit unmet needs could improve eu oncologic drug approval process by ryan scott march 27th 2024 investigators emphasize the importance of firming a widely understood definition of unmet needs in cancer care due to their impact on drug approvals fda grants priority review to revumenib for r r kmt2a aml all by chris ryan march 26th 2024 the fda granted priority review to the nda seeking the approval of revumenib for the treatment of relapsed refractory kmt2a rearranged acute leukemia navigating first line treatment options in advanced unresectable hcc by ryan scott march 26th 2024 pierre gholam md discusses primary considerations for the first line treatment of patients with advanced unresectable hcc shifting therapies to earlier settings could bolster treatment options in mhspc and oligometastatic prostate cancer by jax dieugenio march 26th 2024 neeraj agarwal md fasco discusses unmet needs across the prostate cancer spectrum and ongoing trials investigating agents in earlier settings first line osimertinib plus chemo demonstrates consistent benefit in egfr mutant nsclc by courtney flaherty march 26th 2024 osimertinib plus chemotherapy confers superior post progression survival outcomes vs osimertinib alone in patients with egfr mutated nsclc rutgers cancer institute of new jersey and rwjbarnabas health retains its position as new jersey s only national cancer institute designated comprehensive cancer center by rutgers cancer institute of new jersey march 26th 2024 rutgers cancer institute of new jersey along with rwjbarnabas health was redesignated by the national cancer institute japan s mhlw approves zolbetuximab in cldn18 2 positive gastric cancer by kyle doherty march 26th 2024 the japanese ministry of health labour and welfare has approved zolbetuximab for cldn18 2 positive unresectable advanced or recurrent gastric cancer sls009 generates positive topline data in r r aml and regal trial completes enrollment by ashling wahner march 26th 2024 positive phase 2a topline findings have been announced with sls009 plus azacitidine and venetoclax in relapsed refractory acute myeloid leukemia luspatercept provides effective first line alternative to esas in lower risk mds by courtney flaherty march 26th 2024 sunil iyer md expands on the impact of the fda s approval of luspatercept on the management of lower risk myelodysplastic syndrome handling parenting pressures by kyle doherty march 26th 2024 recent report details the issues early career oncologists experience regarding parental leave unpacking the significance of liso cel s fda approval and continued investigation in cll sll by courtney flaherty march 25th 2024 saad j kenderian mb chb expands on the significance of liso cel s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma first line anlotinib plus etoposide and carboplatin improves pfs in es sclc by ryan scott march 25th 2024 anlotinib plus etoposide carboplatin and placebo improved pfs vs etoposide plus carboplatin and 2 placebos in first line es sclc see all news latest conference coverage mk 1084 alone and plus pembrolizumab shows early safety activity in kras g12c solid tumors first line anlotinib plus etoposide and carboplatin improves pfs in es sclc concurrent durvalumab crt does not confer significant survival advantage in unresectable stage iii nsclc phase 2 imscin002 study shows patients with nsclc prefer subcutaneous atezolizumab view more latest conference coverage advertise about onclive editorial board cancernetwork com cgtlive com curetoday com oncnursingnews com targetedonc com contact us privacy terms conditions do not sell my information contact info 2 commerce drive cranbury nj 08512 609 716 7777 2024 mjh life sciences all rights reserved home about us news contact
|